Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iBio, Inc.IBIO · Entity 6906 | Director | October 14, 2026 | October 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iBio, Inc.
Report date October 14, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2036-10-13 | Direct | 38,000 |
Reported balance
After 2026-10-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-14 · Grant · Acquired 38,000 · Balance 38,000 F1: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 35,509 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.19 · Expires 2021-06-14 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.87 · Expires 2022-06-13 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.42 · Expires 2023-06-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.18 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.97 · Expires 2026-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-01 · Disposition to issuer · Disposed 11,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-01 · Disposition to issuer · Disposed 11,207 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-01 · Disposition to issuer · Disposed 8,855 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2026 Filed Oct 15, 2026 22:34 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-26-116322 · tm2627695-6_4seq1.xml · derivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2036-10-13 F1 · security: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date. F1 · shares: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date. F1 · derivative.exercise_date: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| May 18, 2026 Filed May 19, 2026 11:44 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001104659-26-063503 · tm2615041-1_4seq1.xml · derivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-05-17 F1 · derivative.exercise_date: Vesting monthly on a pro rata basis over 36 months. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $38.09 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 10 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $12.64 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 9 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,855 | Not disclosed Strike: $22.30 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 8 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,855 shares Expires 2028-06-20 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,207 | Not disclosed Strike: $17.20 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 7 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,207 shares Expires 2027-06-20 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,000 | Not disclosed Strike: $10.97 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 6 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2026-06-23 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,750 | Not disclosed Strike: $22.18 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 5 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,750 shares Expires 2025-06-10 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,750 | Not disclosed Strike: $14.42 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 4 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,750 shares Expires 2023-06-11 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,750 | Not disclosed Strike: $14.87 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,750 shares Expires 2022-06-13 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,750 | Not disclosed Strike: $18.19 | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · derivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,750 shares Expires 2021-06-14 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerCommon Stock | 35,509 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-010064 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:45 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $38.09 | $0.00 |
DisclosureSEC source: 0001179110-20-007754 · edgar.xml · derivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Stoner's continued service to the Company. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 22:13 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $13.16 | $0.00 |
DisclosureSEC source: 0001179110-20-000619 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,750 shares Expires 2024-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 22:13 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 4,236 | $25.00 | $105,900.00 |
DisclosureSEC source: 0001179110-20-000619 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,509 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 22:13 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 5,750 | $13.16 | $75,670.00 |
DisclosureSEC source: 0001179110-20-000619 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Unit · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008020 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F3 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008020 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001179110-19-008020 · edgar.xml · derivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Stoner's continued service to the Company. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 20:47 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $13.16 | $0.00 |
DisclosureSEC source: 0001179110-18-010969 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 6,000 shares Expires 2024-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 20:47 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 4,152 | $27.33 | $113,474.16 |
DisclosureSEC source: 0001179110-18-010969 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,639 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.20 to $27.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 20:47 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 6,000 | $13.16 | $78,960.00 |
DisclosureSEC source: 0001179110-18-010969 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:01 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $13.16 | $0.00 |
DisclosureSEC source: 0001179110-18-009628 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 Underlying: Common Stock · 6,000 shares Expires 2024-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:01 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 4,462 | $23.00 | $102,626.00 |
DisclosureSEC source: 0001179110-18-009628 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,791 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:01 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 6,000 | $13.16 | $78,960.00 |
DisclosureSEC source: 0001179110-18-009628 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 2,288 | $22.20 | $50,793.60 |
DisclosureSEC source: 0001179110-18-008963 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,253 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.15 to $22.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008963 · edgar.xml · derivative · entry 5 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F7 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F7 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008963 · edgar.xml · derivative · entry 4 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,356 Underlying: Common Stock · 4,356 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F5 · derivative.exercise_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Stoner's continued service to the Company. F5 · derivative.expiration_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Stoner's continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 8,855 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0001179110-18-008963 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Underlying: Common Stock · 8,855 shares Expires 2028-06-20 F3 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Stoner's continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008963 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,980 | $0.00 Strike: $12.34 | $0.00 |
DisclosureSEC source: 0001179110-18-005927 · edgar.xml · derivative · entry 6 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,980 shares Expires 2020-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 3,842 | $20.00 | $76,840.00 |
DisclosureSEC source: 0001179110-18-005927 · edgar.xml · nonDerivative · entry 4 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,807 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 4,980 | $12.34 | $61,453.20 |
DisclosureSEC source: 0001179110-18-005927 · edgar.xml · nonDerivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20 | $0.00 Strike: $12.34 | $0.00 |
DisclosureSEC source: 0001179110-18-005927 · edgar.xml · derivative · entry 5 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,980 Underlying: Common Stock · 20 shares Expires 2020-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 15 | $20.00 | $300.00 |
DisclosureSEC source: 0001179110-18-005927 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,669 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:22 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 20 | $12.34 | $246.80 |
DisclosureSEC source: 0001179110-18-005927 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 12, 2018 Filed Apr 13, 2018 20:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.34 | $0.00 |
DisclosureSEC source: 0001179110-18-005633 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 10,000 shares Expires 2020-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 12, 2018 Filed Apr 13, 2018 20:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 7,714 | $20.00 | $154,280.00 |
DisclosureSEC source: 0001179110-18-005633 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,664 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 12, 2018 Filed Apr 13, 2018 20:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 10,000 | $12.34 | $123,400.00 |
DisclosureSEC source: 0001179110-18-005633 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:40 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001179110-18-005602 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:40 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 3,399 | $19.00 | $64,581.00 |
DisclosureSEC source: 0001179110-18-005602 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,378 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:40 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 5,000 | $8.85 | $44,250.00 |
DisclosureSEC source: 0001179110-18-005602 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 21, 2018 Filed Apr 12, 2018 20:40 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001179110-18-005603 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2019-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 21, 2018 Filed Apr 12, 2018 20:40 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 3,399 | $19.00 | $64,581.00 |
DisclosureSEC source: 0001179110-18-005603 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,777 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 21, 2018 Filed Apr 12, 2018 20:40 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 5,000 | $8.85 | $44,250.00 |
DisclosureSEC source: 0001179110-18-005603 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 21:43 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,200 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001179110-18-001327 · edgar.xml · derivative · entry 3 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,200 shares Expires 2018-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 21:43 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 16,264 | $18.00 | $292,752.00 |
DisclosureSEC source: 0001179110-18-001327 · edgar.xml · nonDerivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,176 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 21:43 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 19,200 | $13.40 | $257,280.00 |
DisclosureSEC source: 0001179110-18-001327 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 17:27 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 5,500 | $13.10 | $72,050.00 |
DisclosureSEC source: 0001179110-17-015411 · edgar.xml · nonDerivative · entry 1 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,240 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.90 to $13.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 19:57 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009444 · edgar.xml · derivative · entry 2 Stoner Elizabeth · CIK 0001415739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Underlying: Common Stock · 5,734 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Stoner's continued service to the Company. F3 · derivative.expiration_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Stoner's continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.